Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Artificial Intelligence (AI) in Drug Discovery

Published by Global Industry Analysts, Inc. Product code 994402
Published Content info 142 Pages
Delivery time: 1-2 business days
Price
Back to Top
Artificial Intelligence (AI) in Drug Discovery
Published: April 1, 2021 Content info: 142 Pages
Description

Abstract:

Global Artificial Intelligence (AI) in Drug Discovery Market to Reach $2.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Artificial Intelligence (AI) in Drug Discovery estimated at US$589.5 Million in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2027, growing at a CAGR of 25.7% over the analysis period 2020-2027. Oncology, one of the segments analyzed in the report, is projected to record a 22.4% CAGR and reach US$722.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Neurodegenerative Diseases segment is readjusted to a revised 23.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $176.3 Million, While China is Forecast to Grow at 25.2% CAGR

The Artificial Intelligence (AI) in Drug Discovery market in the U.S. is estimated at US$176.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$511.4 Million by the year 2027 trailing a CAGR of 25.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 22.7% and 22.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 18.3% CAGR.

Metabolic Diseases Segment to Record 27.5% CAGR

In the global Metabolic Diseases segment, USA, Canada, Japan, China and Europe will drive the 27.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$87 Million in the year 2020 will reach a projected size of US$475.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$351.2 Million by the year 2027.

Select Competitors (Total 36 Featured) -

  • Atomwise, Inc.
  • Benevolentai
  • Berg LLC
  • Bioage
  • Cloud Pharmaceuticals, Inc.
  • Cyclica
  • Deep Genomics
  • Envisagenics
  • Exscientia
  • Google (A Subsidiary of Alphabet Inc.)
  • IBM Corporation
  • Insilico Medicine
  • Microsoft Corporation
  • Numedii, Inc.
  • Numerate
  • NVIDIA Corporation
  • Owkin, Inc.
  • Twoxar, Incorporated
  • Verge Genomics
  • Xtalpi, Inc.
Table of Contents
Product Code: MCP21177

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
    • TABLE 3: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 5: World Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Metabolic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World 7-Year Perspective for Metabolic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 9: World Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 10: World 7-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 11: World Current & Future Analysis for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 12: World 7-Year Perspective for Infectious Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World 7-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 15: World Current & Future Analysis for Drug Optimization & Repurposing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 16: World 7-Year Perspective for Drug Optimization & Repurposing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 17: World Current & Future Analysis for Preclinical Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 18: World 7-Year Perspective for Preclinical Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 21: USA Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 22: USA 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 23: USA Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 24: USA 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
  • CANADA
    • TABLE 25: Canada Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 27: Canada Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 28: Canada 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
  • JAPAN
    • TABLE 29: Japan Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 30: Japan 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 31: Japan Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
  • CHINA
    • TABLE 33: China Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 34: China 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 35: China Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 36: China 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
  • EUROPE
    • TABLE 37: Europe Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 38: Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
    • TABLE 39: Europe Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 40: Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 41: Europe Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 42: Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
  • FRANCE
    • TABLE 43: France Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: France 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 45: France Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 46: France 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
  • GERMANY
    • TABLE 47: Germany Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 48: Germany 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 49: Germany Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Germany 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
  • ITALY
    • TABLE 51: Italy Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 52: Italy 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 53: Italy Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 54: Italy 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
  • UNITED KINGDOM
    • TABLE 55: UK Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: UK 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 57: UK Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 58: UK 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
  • REST OF EUROPE
    • TABLE 59: Rest of Europe Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 60: Rest of Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 61: Rest of Europe Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Rest of Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 63: Asia-Pacific Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 64: Asia-Pacific 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 65: Asia-Pacific Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 66: Asia-Pacific 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027
  • REST OF WORLD
    • TABLE 67: Rest of World Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Rest of World 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2020 & 2027
    • TABLE 69: Rest of World Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 70: Rest of World 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 36
Back to Top